<DOC>
	<DOCNO>NCT02837757</DOCNO>
	<brief_summary>Everolimus inhibitor mammalian target rapamycin , approve patient metastatic renal cell carcinoma . The objective study investigate influence everolimus immune modulation antitumor efficacy .</brief_summary>
	<brief_title>Everolimus Modulation Anti-tumor T CD4 Immune Responses</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Performance status ECOGWHO 0 , 1 2 Metastatic renal cancer Patient candidate everolimus treatment sign write informed consent fertile woman adequate contraception study 8 week stop treatment Patients chronic treatment systemic corticoid immunosuppressive drug ( prednisone prednisolone â‰¤ 10 mg/day allow ) History immune deficiency Hypersensitivity rapamycin derive Prior history malignancy except : basal cell carcinoma skin , cervical intraepithelial neoplasia cancer curatively treat evidence disease least 5 year Active autoimmune disease , HIV , hepatitis C B virus Patients medical psychiatric condition disease , Patients guardianship , curatorship protection justice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>